Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of dual costimulation blockade with VIB4920 and belatacept to prevent allograft rejection in adults receiving a kid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Renal Allograft Rejection

Drugs mentioned

• VIB4920 (VIB4920)
• belatacept (belatacept)

Snippet

Sponsor: Amgen | Conditions: Allografts, Rejection; Transplant, Kidney | Phase 2 | Status: COMPLETED | Results posted: 2023-10-10